Entities / Company
VIR Biotechnology.
biotech company
- Reports this week
- 0
- Active events
- 0
- Connections
- 42
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Brii Biosciences and VIR Biotechnology engaged regarding chronic hepatitis B virus therapies, including an arbitration over manufacturing technology transfer.Some support3 reports
-
The ECLIPSE program is the registrational program for Vir Biotechnology.Some support1 report
-
The ECLIPSE program is the registrational program for Vir Biotechnology, and the trial supports global marketing in Europe.Some support1 report
-
Dr. Alan J. Korman was appointed to Invenra's Scientific Advisory Board, where Roland Green serves as CEO.Some support1 report
-
Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.Some support1 report1 development inside
-
VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.Some support1 report
-
Vir Biotechnology shares lost 30.4% on August 7, 2025, against a gain in the S&P 500.Some support1 report
-
CEO of VIR Biotechnology participated in a conference chat hosted by Morgan Stanley on August 26, 2025.Some support1 report
-
Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around VIR Biotechnology this week
News at the entities that move VIR Biotechnology most-
Raymond James Financial Mentioned togetherPrimis Financial filed 13F reports with the SEC regarding institutional holdings, accompanied by analyst reports and price targets.Moves VIR Biotechnology
-
Morgan Stanley TransactionalCitigroup upgraded Next plc to a buy rating, while Santander and Morgan Stanley also issued rating updates on the company.Moves VIR Biotechnology
-
SEC StructuralLaser Photonics Corporation hired Tim Peterman as Chief Financial Officer and engaged CBIZ for financial reporting consulting.Moves VIR Biotechnology
-
Renaissance Technologies TransactionalXiaomi stock is listed on Nasdaq, and Renaissance Technologies boosted its stake in the company.Moves VIR Biotechnology
-
Netherlands Shared contextIrish beef is being promoted and marketed in Belgium, Italy, and the Netherlands by Irish companies and Bord Bia.Moves VIR Biotechnology
Connections
The 7 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Astellas Pharma Operational
Astellas Pharma and VIR Biotechnology are collaborating on the joint development of a PSMA-targeted T-cell engager.
-
Morgan Stanley Transactional
Morgan Stanley issued a price objective for VIR Biotechnology, reflecting financial assessment.
-
SEC Structural
VIR Biotechnology is subject to mandatory filings and oversight by the U.S. Securities and Exchange Commission.
-
Renaissance Technologies Transactional
Renaissance Technologies increased its investment holdings in VIR Biotechnology shares.
-
Janet Napolitano Transactional
Janet Napolitano sold shares of VIR Biotechnology.
-
Raymond James Financial Mentioned together
Raymond James Financial provided a strong-buy rating on VIR Biotechnology.
-
Netherlands Shared context
VIR Biotechnology conducts clinical data presentations within the Netherlands.
History
Events by the month they beganOctober 2026
2 eventsAugust 2026
1 eventShow 1 earlier month
June 2026
8 events- The ECLIPSE program is the registrational program for Vir Biotechnology.
- The ECLIPSE program is the registrational program for Vir Biotechnology, and the trial supports global marketing in Europe.
- Dr. Alan J. Korman was appointed to Invenra's Scientific Advisory Board, where Roland Green serves as CEO.
- Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
- VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.
- Vir Biotechnology shares lost 30.4% on August 7, 2025, against a gain in the S&P 500.
- CEO of VIR Biotechnology participated in a conference chat hosted by Morgan Stanley on August 26, 2025.
- Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.